SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
IKT reported Third Quarter 2026 results. The price and volatility reaction is pending.
IKTearnings

Earnings reactions, page 3

Inhibikase Therapeutics, Inc. (IKT) Q3 FY2026 earnings

November 11, 2026 · SharpeIQ Research Desk

Reported results

  • GAAP net loss for the quarter ended September 30, 2026, was $20.5 million, or $0.10 per share.
  • GAAP research and development expenses were $15.0 million for the quarter ended September 30, 2026.
  • GAAP selling, general and administrative expenses for the quarter ended September 30, 2026, were $7.2 million.
  • As of September 30, 2026, cash, cash equivalents and marketable securities were $193.3 million.
  • As of September 30, 2026, there were 140.3 million shares of common stock and 60.6 million pre-funded warrants outstanding.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-10 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →